The role of lipids in renal disease: Future challenges

Kidney International, Supplement

Volumn 57, Issue 75, 2000, Pages

  Keane, William F ^a  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; Diabetes; Microalbuminuria

Indexed keywords

ALBUMIN; ANTILIPEMIC AGENT; APOLIPOPROTEIN A; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CHOLESTEROL; COLONY STIMULATING FACTOR 1; CREATININE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; ENDOTHELIN; ENDOTHELIUM DERIVED RELAXING FACTOR; FIBRINOGEN; GROWTH FACTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; REACTIVE OXYGEN METABOLITE; RENIN; THROMBOXANE; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; DIABETES MELLITUS; DRUG MECHANISM; DYSLIPIDEMIA; HUMAN; INFLAMMATION; KIDNEY DISEASE; KIDNEY INJURY; MICROALBUMINURIA; NONHUMAN; PRIORITY JOURNAL; ALBUMINURIA; ANIMAL; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; HYPERLIPIDEMIA; HYPERTENSION; REVIEW;

ALBUMINURIA; ANIMALS; DIABETES COMPLICATIONS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; LIPID METABOLISM, INBORN ERRORS;

EID: 0034034681     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.07503.x     Document Type: Conference Paper

References (51)

1. MOGENSEN CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356-360, 1984
2. MESSENT JW, ELLIOT TG, HILL RG, JARRETT RJ, KEEN H, VIBERTI GC: Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three-year follow-up study. Kidney Int 41:836-839, 1992
3. ROSSING P, HOMMEL E, SMIDT UM, PARVING HH: Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropalhy in IDDM patients. Diabetes 42:715-719, 1993
4. VIBERTI GC, HILL RD, JARRETT RJ, ARGYROPOULOS A, MAHMUD U, KEEN H: Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellilus. Lancet i:1430-1432, 1982
5. JARRETT RJ, VIBERTI GC, ARGYROPOULOS A, HILL RD, MAHMUD U, MURRELS TJ: Microalbuminuria predicts mortality in non-insulin-dependent diabetics. Diabetes Med 1:17-19, 1984
6. SCHMITZ A, VAETH M: Microalbuminuria: a major risk factor in non-insulin-dependent diabetes. A ten-year follow-up study of 503 patients. Diabetes Med 5:126-134, 1988
7. COLLINS VR, DOWSE GK, FINCH CF, ZIMMET PZ, LINNANE AW: Prevalence and risk factors for micro-and macroalbuminuria in diabetic subjects and entire population of Nauru. Diabetes 38:1602-1610, 1989
8. GERBER LM, SHMUKLER C, ALDERMAN MH: Differences in urinary albumin excretion rate between normotensive and hypertensive white and non-white subjects. Arch Intern Med 152:373-377, 1992
9. D'AGOSTINO RB, KANNEL WB, STEPANIANS MN, D'AGOSTINO LC: Efficacy and tolerability of lovastatin in hypercholesterolemia in patients with systemic hypertension. Am J Cardiol 71:82-87, 1993
10. WINOCOUR PH, HARLAND JO, MILLAR JP, LAKER MF, ALBERTI KG: Microalbuminuria and associated cardiovascular risk factors in the community. Atherosclerosis 93:71-81, 1992
11. CERASOLA G, COTTONE S, MULE G, NARDI E, MANGANO MT, ANDRONICO G, CONTORNO A, LI VECCHI M, GAGLIONE P, RENDA F, PIAZZA G, VOLPE V, LISI A, FERRARA L, PANEPINTO N, RICCOBENE R: Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension. J Hypertens 14:915-920, 1996
12. GRIMM RH, SVENDSEN KH, KASISKE BL, KEANE WF, WAHI M: Proteinuria is a risk factor for mortality over 10 years of follow-up. The MRFIT Research Group. Kidney Int 52 (Suppl. 63):S-10-S-14, 1997
13. BIGAZZI R, BIANCHI S, BALDARI D, CAMPESE VM: Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 16:1325-1333, 1998
14. SCHMIEDER RE, VEELKEN R, GATZKA CD, RUDDLE H, SCHACHINGER H: Predictors for hypertensive nephropathy: results of seven years of follow-up in essential hypertension. J Hypertens 13:357-365, 1994
15. RUILOPE LM, CAMPO C, RODRIGUEZ-ARTALEJO F, LAHERA V, GARCIA ROBLES R, RODICIO JL: Blood pressure and renal function: therapeutic implications. J Hypertens 14:1259-1263, 1996
16. BIANCHI S, BIGAZZI R, BALDARI G, SGHERRI G, CAMPESE VM: Diurnal variation of blood pressure and microalbuminuria in essential hypertension. Am J Hypertens 7:23-29, 1994
17. EQUILUZ-BRUCK S, SCHNACK C, KOPP HP, SCHERNTHANER G: Nondipping of nocturnal blood pressure is related to urinary albumin excretion rate in patients with type 2 diabetes mellitus. Am J Hypertens 9:1139-1143, 1996
18. BALDONCINI R, DESIDERI G, BELLINI C, VALENTI M, DE MATTIA G, SANTUCCI A, FERRI C: High plasma renin activity is combined with elevated urinary albumin excretion in essential hypertensive patients. Kidney Int 56:1499-1504, 1999
19. TUTTLE KR, PUHLMAN ME, COONEY SK, SHORT R: Urinary albumin and insulin as predictors of coronary artery disease: an angiographic study. Am J Kidney Dis 34:918-925, 1999
20. MOGENSEN CE, CHRISTENSEN CK: Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311:89-93, 1984
21. PARVING H-H, OXENBOLL B, SVENDSEN PA, CHRISTIANSEN JS, ANDERSEN AR: Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion. Acta Endocrinol 100:550-555, 1982
22. PYÖRÄLÄ K, PEDERSEN TR, KJEKSHUS J, FAERGEMAN O, OLSSON AG, THORGEIRSSON G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620, 1997
23. PLEHN JF, DAVIS BR, SACKS FM, ROULEAU JL, PFEFFER MA, BERNSTEIN V, CUDDY TE, MOYE LA, PILLER LB, RUTHERFORD J, SIMPSON LM, BRAUNWALD E: Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 19:216-223, 1999
24. BREYER JA, BAIN RP, EVANS JK, NAHMAN NS, LEWIS EJ, COOPER M, MCGILL J, BERL T: Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney Int 50:1651-1658, 1996
25. RAVID M, BROSH D, RAVID-SAFRAN D, LEVY Z, RACHMANI R: Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 158:998-1004, 1998
26. GAEDE P, VEDEL P, PARVING H-H, PEDERSEN O: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353:617-622, 1999
27. SAMUELSSON O, MULEC H, KNIGHT-GIBSON C, ATIMAN P-O, KRON B, LARSSON R, WEISS L, WEDEL H, ALAUPOVIC P: Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 12:1908-1915, 1997
28. YANG WQ, SONG NG, YING SS, LIANG HQ, ZHANG YJ, WEI MJ, WU KF: Serum lipid concentrations correlate with the progression of chronic renal failure. Clin Lab Sci 12:104-108, 1999
29. SAITO T: Abnormal lipid metabolism and renal disorders. Tohoku J Exp Wed 181:321-337, 1997
30. OIKAWA S, MATSUNAGA A, SAITO T, SATO H, SEKI T, HOSHI K, HAYASAKA K, KOTAKE H, MIDORIKAWA H, SEKIKAWA A, HARA S, ABE K, TOYOTA T, JINGAMI H, NAKAMURA H, SASAKI J: Apolipoproein E Sendai (arginine 145 proline): a new variant associated with lipoprotein glomerulopathy. J Am Soc Nephrol 8:820-823, 1997
31. ANDO M, SASAKI J, HUA H, MATSUNAGA A, UCHIDA K, JOU K, OIKAWA S, SAITO T, NIHEI H: A novel 18-amino acid deletion in apolipoprotein E associated with lipoprotein glomerulopathy. Kidney Int 56:1317-1323, 1999
32. KEANE WF: Lipids and progressive renal failure. Wien Klin Wochenschr 14:420-424, 1996
33. INMAN SR, STOWE NT, CRESSMAN MD, BROUHARD BH, NALLY JV, SATOH S, SATODATE, R, VIDT DG: Lovastatin preserves renal function in experimental diabetes. Am J Med Sci 317:215-221, 1999
34. MAGIL AB: Interstitial foam cells and oxidized lipoprotein in human glomerular disease. Mod Pathol 12:33-40, 1999
35. KEANE WF, O'DONNELL MP, KASISKE BL, KIM Y: Oxidative modification of low density lipoproteins by mesangial cells. J Am Soc Nephrol 4:187-194, 1993
36. GALLE J, HEERMEIER K: Angiotensin II and oxidized LDL. An unholy alliance creating oxidative stress. Nephrol Dial Transplant 14:1585-2589, 1999
37. ODA H, KEANE WF: Recent advances in statins and the kidney. Kidney Int 56 (Suppl. 71):S-2-S-5, 1999
38. GUIJARRO C, KIM Y, SCHOONOVER CM, MASSY ZA, O'DONNELL MP, KASISKE BL, KEANE WF, KASHTAN CE: Lovastatin inhibits lipopolysaccharide-induced NF-κB activation in human mesangial cells. Nephrol Dial Transplant 11:990-996, 1996
39. GUIJARRO C, KEANE WF: Effects of lipids on the pathogenesis of progressive renal failure: Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis. Miner Electrolyte Metab 22:147-152, 1996
40. O'DONNELL MP, KASISKE BL, KIM Y, AILURU D, KEANE WF: Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 91:83-87, 1993
41. VRTOVSNIK F, COUETTE S, PRIE D, LALIEMAND D, FRIEDLANDER G: Lovastalin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway. Kidney Int 52:1016-1027, 1997
42. ROGLER G, LACKNER KJ, SCHMITZ G: Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro. Am J Cardiol 76:114A-116A, 1995
43. GUIJARRO C, BLANCO-COLIO LM, ORTEGO M, ALONSO C, ORTIZ A, PLAZA JJ, DIAZ C, HERNANDEZ G, EGIDO J: 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 83:490-500, 1998
44. KASISKE BL, O'DONNELL MP, KIM Y, AILURU D, KEANE WF: Cholesterol synthesis inhibitors inhibit more than cholesterol synthesis. Kidney Int 45 (Suppl. 45):S51-S53, 1994
45. KIM SY, GUIJARRO C, O'DONNELL MP, KASISKE BL, KIM Y, KEANE WF: Human mesangial cell production of monocyte chemoattractant protein-1: modulation by lovastalin. Kidney Int 48:363-371, 1995
46. PARK YS, GUIJARRO C, KIM Y, MASSY ZA, KASISKI BL, KEANE WF, O'DONNELL MP; Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis 31:190-194, 1998
47. FUKADA Y, TAKAO T, OHGURO H, YOSHIZAWA T, AKINO T, SHIMONISHI Y: Farnesylated g-subunit of photoreceptor G protein indispensable for GTP-binding. Nature 346:658-660, 1990
48. BARBU V, DAUIRY F: Mevalonate deprivation alters the induction of fos and myc by growth factors. Oncogene 5:1077-1080, 1990
49. ODA H, KASISKE BL, O'DONNELL MP, KEANE WF: Effects of lovastatin on expression of cell cycle regulatory proteins in vascular smooth muscle cells. Kidney Int 56 (Suppl. 71):S-202-S-205, 1999
50. HIRAI A, NAKAMURA S, NOGUCHI Y, YASUDA T, KITAGAWA M, TATSUNO I, OEDA T, TAHARA K, TERANO T, NARUMIYA S, KOHN LD, SAITO Y: Geranylgeranylated rho small GTPase (s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem 272:13-16, 1997
51. HENGSI L, REED SI: Translation control of p27Kip1 accumulation during the cell cycle. Science 271:1861-1864, 1996